Kinvard is a preclinical biotech with an IV/oral compound targeting gram-negative and positive pathogens, leveraging technology from Harvard University and non-dilutive funding from CARB-X.
Clarametyx is a clinical-stage biotech developing anti-biofilm antibodies for cystic fibrosis and other respiratory infections
Orthobond has developed a coating for medical device implants to prevent biofilm formation and infection from orthopedic surgery.
Endolytix is using enzymes from bacteriophages to target antibiotic resistant nontuberculous mycobacteria (NTM) that cause chronic lung disease.
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.
Promaxo develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' lives and redefine the standard of care.
neuro42, Inc. is a medtech Company advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions.
Kincell is a technology-forward contract development and manufacturing organization (CDMO).
Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs.